NSCLC molecular testing in Central and Eastern European countries

Creative Commons License

Ryska A., Berzinec P., Brcic L., Cufer T., Dziadziuszko R., Gottfried M., et al.

BMC CANCER, cilt.18, 2018 (SCI İndekslerine Giren Dergi)


Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines.